FI883603A0 - Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi

Info

Publication number
FI883603A0
FI883603A0 FI883603A FI883603A FI883603A0 FI 883603 A0 FI883603 A0 FI 883603A0 FI 883603 A FI883603 A FI 883603A FI 883603 A FI883603 A FI 883603A FI 883603 A0 FI883603 A0 FI 883603A0
Authority
FI
Finland
Prior art keywords
methyl
preparation
therapeutically useful
dihydropyridine derivatives
substd
Prior art date
Application number
FI883603A
Other languages
English (en)
Swedish (sv)
Other versions
FI883603A (fi
FI91406B (fi
FI91406C (fi
Inventor
Carlos Fernandez Torija
Joaquin Alvaro Galiano Ramos
Original Assignee
Delagrange Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delagrange Lab filed Critical Delagrange Lab
Publication of FI883603A0 publication Critical patent/FI883603A0/fi
Publication of FI883603A publication Critical patent/FI883603A/fi
Publication of FI91406B publication Critical patent/FI91406B/fi
Application granted granted Critical
Publication of FI91406C publication Critical patent/FI91406C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI883603A 1987-08-03 1988-08-01 Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi FI91406C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP87401799 1987-08-03
EP87401799A EP0302980B1 (fr) 1987-08-03 1987-08-03 1,4-Dihydropyridines, leur procédé de préparation et leur application comme médicaments

Publications (4)

Publication Number Publication Date
FI883603A0 true FI883603A0 (fi) 1988-08-01
FI883603A FI883603A (fi) 1989-02-04
FI91406B FI91406B (fi) 1994-03-15
FI91406C FI91406C (fi) 1994-06-27

Family

ID=8198243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI883603A FI91406C (fi) 1987-08-03 1988-08-01 Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi

Country Status (34)

Country Link
US (1) US4952592A (fi)
EP (1) EP0302980B1 (fi)
JP (1) JPH0733383B2 (fi)
KR (1) KR960001724B1 (fi)
CN (1) CN1038587C (fi)
AT (1) ATE61588T1 (fi)
BE (1) BE1001055A4 (fi)
CA (2) CA1306261C (fi)
CH (1) CH675999A5 (fi)
CZ (1) CZ282077B6 (fi)
DD (1) DD282008A5 (fi)
DE (2) DE3768658D1 (fi)
DK (1) DK430288A (fi)
ES (1) ES2007543A6 (fi)
FI (1) FI91406C (fi)
GB (1) GB2208861B (fi)
GR (2) GR880100507A (fi)
HU (1) HU204523B (fi)
IE (1) IE60358B1 (fi)
IL (1) IL87321A (fi)
IN (1) IN167550B (fi)
IS (1) IS1549B (fi)
IT (1) IT1235013B (fi)
LU (1) LU87297A1 (fi)
MA (1) MA21344A1 (fi)
NO (1) NO170934C (fi)
NZ (1) NZ225661A (fi)
PH (1) PH25645A (fi)
PT (1) PT88173B (fi)
RU (1) RU2036922C1 (fi)
SK (1) SK278775B6 (fi)
TN (1) TNSN88081A1 (fi)
YU (1) YU46547B (fi)
ZA (1) ZA885684B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242933A (en) * 1990-07-10 1993-09-07 Adir Et Compagnie Piperidine, tetrahydropyridine and pyrrolidine compounds
ES2166462T3 (es) * 1995-08-02 2002-04-16 Smithkline Beecham Corp Antagonistas del receptor de la endotelina.
ES2287110T3 (es) * 2000-04-11 2007-12-16 Sankyo Company, Limited Composicion farmaceutica estabilizada que contiene un bloqueador de calcio consistente en azelnidipina.
ES2362998T3 (es) 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
BRPI0513866A (pt) * 2004-07-26 2008-05-20 Cotherix Inc composição, micropartìculas, método para o tratamento da hipertensão pulmonar, e dispositivo de inalação
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
EP1951253A2 (en) 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TW200736245A (en) * 2005-11-29 2007-10-01 Sankyo Co Acid addition salts of optically active dihydropyridine derivatives
TW200806648A (en) * 2005-11-29 2008-02-01 Sankyo Co Acid addition salts of dihydropyridine derivatives
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
WO2012037665A1 (en) 2010-09-24 2012-03-29 Oral Delivery Technology Ltd. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA3125765A1 (en) 2019-01-18 2020-07-23 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3441648A (en) * 1967-02-07 1969-04-29 Smithkline Corp Compositions and methods for lowering blood pressure with 1,4-dihydropyridines
US4031104A (en) * 1972-04-18 1977-06-21 Bayer Aktiengesellschaft 1,4-Dihydropyridine carboxylic acid esters
JPS5978186A (ja) * 1982-10-27 1984-05-04 Yoshitomi Pharmaceut Ind Ltd １，４−ジヒドロピリジン−３，５−ジカルボン酸エステル誘導体
IE57810B1 (en) * 1984-03-27 1993-04-21 Delagrange Lab 1,4-dihydropyridine derivatives,their preparation and their use
ES531033A0 (es) * 1984-03-27 1985-09-01 Inst Investigacion Desarrollo Un procedimiento para la preparacion de nuevas 1,4-dihidropirinas-4-(polioxialquilfenil)-sustituidas
JPH068294B2 (ja) * 1985-02-26 1994-02-02 富山化学工業株式会社 新規な１，４−ジヒドロピリジン誘導体およびその塩
EP0174131A3 (en) * 1984-09-01 1989-06-07 FISONS plc Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
JPH01207267A (ja) * 1987-03-05 1989-08-21 Yamanouchi Pharmaceut Co Ltd ピリジン誘導体及び該化合物を含有する肝疾患治療剤

Also Published As

Publication number Publication date
GB8818356D0 (en) 1988-09-07
GB2208861B (en) 1991-07-17
IE882364L (en) 1989-02-03
NZ225661A (en) 1990-08-28
NO170934C (no) 1992-12-30
RU2036922C1 (ru) 1995-06-09
IL87321A0 (en) 1989-01-31
NO883406D0 (no) 1988-08-01
FI883603A (fi) 1989-02-04
CN1031531A (zh) 1989-03-08
PH25645A (en) 1991-08-21
DD282008A5 (de) 1990-08-29
IS3378A7 (is) 1989-02-04
GR880100507A (el) 1989-05-25
HU204523B (en) 1992-01-28
IN167550B (fi) 1990-11-10
ZA885684B (en) 1989-04-26
ES2007543A6 (es) 1989-06-16
FI91406B (fi) 1994-03-15
IS1549B (is) 1994-06-08
US4952592A (en) 1990-08-28
NO170934B (no) 1992-09-21
CZ282077B6 (cs) 1997-05-14
IL87321A (en) 1993-04-04
DK430288D0 (da) 1988-08-02
GB2208861A (en) 1989-04-19
YU46547B (sh) 1993-11-16
YU147088A (en) 1990-04-30
GR3001984T3 (en) 1992-11-23
BE1001055A4 (fr) 1989-06-20
KR960001724B1 (ko) 1996-02-03
CN1038587C (zh) 1998-06-03
HUT54142A (en) 1991-01-28
CA1306261C (fr) 1992-08-11
IE60358B1 (en) 1994-06-29
SK541388A3 (en) 1998-02-04
EP0302980B1 (fr) 1991-03-13
JPH01294675A (ja) 1989-11-28
ATE61588T1 (de) 1991-03-15
KR890003743A (ko) 1989-04-17
PT88173B (pt) 1995-03-01
CA1306262C (fr) 1992-08-11
FI91406C (fi) 1994-06-27
DE3825962A1 (de) 1989-02-16
CH675999A5 (en) 1990-11-30
AU2033088A (en) 1989-02-09
MA21344A1 (fr) 1989-04-01
NO883406L (no) 1989-02-06
DK430288A (da) 1989-02-03
PT88173A (pt) 1989-06-30
EP0302980A1 (fr) 1989-02-15
DE3768658D1 (de) 1991-04-18
IT8848259A0 (it) 1988-08-02
LU87297A1 (fr) 1989-02-02
CZ541388A3 (en) 1997-01-15
TNSN88081A1 (fr) 1990-07-10
IT1235013B (it) 1992-06-16
AU606441B2 (en) 1991-02-07
SK278775B6 (sk) 1998-02-04
JPH0733383B2 (ja) 1995-04-12

Similar Documents

Publication Publication Date Title
FI883603A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,4-dihydropyridiinijohdannaisten valmistamiseksi
FI900307A0 (fi) Menetelmä valmistaa terapeuttisesti aktiivista 3-/3-okso-(2,3)-dihydropyridatsin-6-yyli/-2-fenyyli-pyratsolo/1,5-a/pyridiinijohdannaisia
FI95704B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridiinijohdannaisten valmistamiseksi
NL940010I2 (nl) Nieuwe 2beta-morfolino-androstaanderivaten en werkwijze voor de bereiding daarvan.
FI91529B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyrido/1,2,3-de//1,4/bentsoksatsiinijohdannaisten valmistamiseksi
NO176713C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 4-aminopyridinderivater
NO173184C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridin-2,4- og 2,5-dikarboksylsyrederivater
FI900145A (fi) Menetelmä farmaseuttisesti käyttökelpoisten 1,1-diokso-kefem-4-karbotiolihappojohdannaisten valmistamiseksi
FI99013B (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten bentsimidatsolijohdannaisten valmistamiseksi
NO177263C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive pyridinderivater
FI893570A (fi) Menetelmä lääkeaineina käyttökelpoisten 1H-imidatso/1,2-b/-pyratsolin johdannaisten valmistamiseksi
NO176277C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3,4-dihydro-2-alkyl-3-okso-N-aryl-2H-[1Åbenzotieno[3,2-eÅ-1,2-tiazin-4-karboksamid-1,1-dioksyder
SE8605255D0 (sv) 4h-benzo(4,5)cyclohepta(1,2-b)thiophene derivatives
FI893121A0 (fi) Menetelmä farmakologisesti aktiivisten 6,21-dimetyyli-19-norprogesteronijohdannaisten valmistamiseksi
GB1232348A (fi)
FI943730A0 (fi) Menetelmä angiotensiini-II-antagonistina aktiivisen 3-(2'-N-bentsoyylisulfonamido-bifen-4-yyli)metyyli-5,7-dimetyyli-2-etyyli-3H-imidatso/4,5-b/pyridiinin valmistamiseksi

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: ALMIRALL-PRODESFARMA S.A.

TC Name/ company changed in patent

Owner name: ALMIRALL-PRODESFARMA S.A.

MM Patent lapsed

Owner name: ALMIRALL-PRODESFARMA S.A.